Expression and Purification of FGFR1-Fc Fusion Protein and Its Effects on Human Lung Squamous Carcinoma
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Molecular-targeted therapies for lung squamous cell carcinoma (LSCC) are limited mainly because targetable oncogenic aberrations are absent in LSCC. Recent genomic analyses have revealed that the fibroblast growth factor (FGF) signaling pathway plays a fundamental role in LSCC progression via cancer cell proliferation and angiogenesis. In the present study, we designed, expressed, and purified a fibroblast growth factor receptor fragment (FGFR1-Fc) fusion protein using NS/0 cells. In FGF2-FGFR1 overexpressed NCI-H1703 cells, the FGFR1-Fc fusion protein effectively inhibited proliferation and invasion and arrested the cell cycle at the G0-G1 phase. In NCI-H1703 cells treated with the FGFR1-Fc fusion protein, the phosphorylation levels of FGFR1, FRS2, ERK, and AKT were significantly reduced. Using an siRNA assay, we demonstrated that FGF2-FGFR1 is the major anti-tumor target of FGFR1-Fc fusion the FGFR1-Fc fusion protein, which also significantly inhibited proliferation and invasion by NCI-H1703 cells via the FGF2-FGFR1 signaling pathway. In addition, the FGFR1-Fc fusion protein significantly inhibited angiogenesis in an embryonic chorioallantoic membrane model. The FGFR1-Fc fusion protein may be an effective therapeutic candidate for LSCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:196 |
|---|---|
| Enthalten in: |
Applied biochemistry and biotechnology - 196(2024), 1 vom: 10. Jan., Seite 573-587 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zheng, Lulu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.01.2024 Date Revised 18.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12010-023-04542-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356635023 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356635023 | ||
| 003 | DE-627 | ||
| 005 | 20240118231845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12010-023-04542-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1263.xml |
| 035 | |a (DE-627)NLM356635023 | ||
| 035 | |a (NLM)37160564 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zheng, Lulu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Expression and Purification of FGFR1-Fc Fusion Protein and Its Effects on Human Lung Squamous Carcinoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2024 | ||
| 500 | |a Date Revised 18.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Molecular-targeted therapies for lung squamous cell carcinoma (LSCC) are limited mainly because targetable oncogenic aberrations are absent in LSCC. Recent genomic analyses have revealed that the fibroblast growth factor (FGF) signaling pathway plays a fundamental role in LSCC progression via cancer cell proliferation and angiogenesis. In the present study, we designed, expressed, and purified a fibroblast growth factor receptor fragment (FGFR1-Fc) fusion protein using NS/0 cells. In FGF2-FGFR1 overexpressed NCI-H1703 cells, the FGFR1-Fc fusion protein effectively inhibited proliferation and invasion and arrested the cell cycle at the G0-G1 phase. In NCI-H1703 cells treated with the FGFR1-Fc fusion protein, the phosphorylation levels of FGFR1, FRS2, ERK, and AKT were significantly reduced. Using an siRNA assay, we demonstrated that FGF2-FGFR1 is the major anti-tumor target of FGFR1-Fc fusion the FGFR1-Fc fusion protein, which also significantly inhibited proliferation and invasion by NCI-H1703 cells via the FGF2-FGFR1 signaling pathway. In addition, the FGFR1-Fc fusion protein significantly inhibited angiogenesis in an embryonic chorioallantoic membrane model. The FGFR1-Fc fusion protein may be an effective therapeutic candidate for LSCC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a FGF2 | |
| 650 | 4 | |a FGFR1 | |
| 650 | 4 | |a FGFR1-Fc fusion protein | |
| 650 | 4 | |a Squamous cell carcinoma | |
| 650 | 7 | |a FP-1039 |2 NLM | |
| 650 | 7 | |a CTG26PRE5S |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factor 2 |2 NLM | |
| 650 | 7 | |a 103107-01-3 |2 NLM | |
| 650 | 7 | |a Receptor, Fibroblast Growth Factor, Type 1 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a FGFR1 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 700 | 1 | |a Liu, Huan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Lingfeng |e verfasserin |4 aut | |
| 700 | 1 | |a You, Xinyi |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Fangyi |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Haibing |e verfasserin |4 aut | |
| 700 | 1 | |a Hui, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Baohua |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaojie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Applied biochemistry and biotechnology |d 1981 |g 196(2024), 1 vom: 10. Jan., Seite 573-587 |w (DE-627)NLM012691364 |x 1559-0291 |7 nnns |
| 773 | 1 | 8 | |g volume:196 |g year:2024 |g number:1 |g day:10 |g month:01 |g pages:573-587 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12010-023-04542-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 196 |j 2024 |e 1 |b 10 |c 01 |h 573-587 | ||